Matthew Johnson

Matthew Johnson is a psychologist whose research at Johns Hopkins University joined a practical question—whether smokers could quit—with a broader account of how psychedelic experiences might loosen entrenched ways of seeing the self. As a researcher and guide, he helped develop psilocybin studies and led a small smoking-cessation pilot. He treated the drug not as a cure acting alone, but as one part of a supported process in which intention, therapy, and a temporarily altered perspective could make change feel possible.

Background and Entry into Research

Johnson’s interest began before he had a professional route into psychedelic science. In college he read Ram Dass and learned about the Harvard Psilocybin Project. The prospect of working with psychedelic compounds stayed in mind, though he did not expect it to become his work in a laboratory.

The project he encountered at Johns Hopkins University in 2004 was initially discreet: soon after arriving for a pharmacology postdoctoral position, Johnson learned that Roland Griffiths was conducting a psilocybin study. The discovery brought together his longstanding interest and a research opportunity he had not thought was near. The book presents him as a behaviorally trained psychologist, with earlier study of subjects such as operant conditioning in rats. Its portrait also marks him as a young researcher of the period, describing a carefully trimmed black beard and oversized black glasses.

That renewed work took place against the legacy of an earlier, less settled era. In 1957, R. Gordon Wasson’s article in Life magazine had introduced the phrase “magic mushrooms” to a mass audience, and Wasson’s account reached millions through the magazine and later television. Timothy Leary read the article on his way to Harvard. Years afterward, the Harvard project became entangled in public controversy: a student newspaper report was followed by sensational coverage, and Leary and Richard Alpert eventually said the work was too controversial for a university setting. By 1966, even Life had shifted from enthusiastic promotion to alarmist warnings about LSD. Johnson’s entry into laboratory research in 2004 thus belonged to a revival after a period when psychedelic research had become both institutionally difficult and publicly suspect; the evidence does not describe him as a participant in the earlier disputes.

Research at Johns Hopkins

Before starting a study of his own, Johnson worked on the laboratory’s early psilocybin studies. He served as a guide in several dozen sessions and helped analyze the data. In 2009 he launched a smoking-cessation pilot focused on people who wanted to quit.

The study enrolled fifteen smokers. Participants received several sessions of cognitive behavioral therapy followed by two or three psilocybin doses. It was open-label, without a placebo group, so the volunteers knew they were receiving psilocybin. They were required to stop smoking before a dosing session, and researchers measured carbon-monoxide levels at intervals to check abstinence and monitor whether it continued.

The results were striking but came with important limits: the study was small and not randomized. Six months after the sessions, 80 percent of participants were confirmed abstinent; at one year, 67 percent remained abstinent, a rate reported as better than the best treatment then available. Participants who had the most complete mystical experiences tended to have the strongest outcomes. Charles Bessant, one of the smokers in the study, had remained abstinent for six years by the time of the account. A larger randomized comparison of psilocybin therapy with the nicotine patch was then underway, offering a more rigorous test than the pilot could provide.

Habit, Intention, and Perspective

Johnson called some of the participants’ realizations “duh moments”: conclusions they might already have known intellectually, such as that smoking was unhealthy, costly, or unnecessary. In his account, the change was not that the facts became new, but that they acquired emotional force. The insights became harder to dismiss or avoid, interrupting the automatic, inattentive patterns in which an addiction could persist.

He understood addiction partly as a constricting story, reinforced by repeated efforts to quit and failures that seemed to confirm helplessness. A psychedelic session could, in his view, give a person distance from that story and place the immediate reward of smoking within the larger span of a life. This was not presented as an inevitable effect of taking psilocybin: many people have taken it and continued to smoke. The pilot’s structure instead made quitting the explicit purpose. Preparation, therapist guidance, and integration after the sessions reinforced that intention. Johnson’s emphasis was therefore on psychedelic-assisted therapy, not medication considered in isolation.

The image of a thought made visible offers one way to understand why an ordinary realization might carry unusual weight. The book describes a participant’s vivid image of herself as a hunched, coughing gargoyle smoking; months later, she could still use the image when cravings arose. For Johnson, this kind of concrete, memorable experience helps explain how someone may move beyond simply knowing a habit is harmful. The altered perspective can make that knowledge more immediate and difficult to evade.

The Self and the Risks of Change

Johnson extended this account beyond smoking. He believed psychedelics might help change a range of behaviors by producing an experience dramatic enough to disrupt a person’s habitual interpretation of reality. In his model, the self-centered pattern of thought is especially important: a high-dose experience can temporarily loosen the ego and the fixed stories built around it. He connected this possibility across addiction, depression, and the preoccupation with death or recurrence experienced by some cancer patients—not as identical problems, but as conditions that can be intensified by rigid narratives about the self.

That disruption carries risks. Johnson warned that loosening a person’s ordinary framework can lead to a bad trip or worse in the wrong circumstances. He raised Charles Manson’s reported use of LSD to break down and manipulate followers as a plausible example of how psychedelic suggestibility could be misused; this was Johnson’s interpretation, not a finding from the smoking study. In a setting designed to assure safety, however, he saw the temporary flexibility as a possible opening for more constructive ways of understanding oneself and one’s relation to the world. He also acknowledged that researchers and doctors guiding people through such a vulnerable state take on a role resembling that of shamans or elders.

Environment and Narrative Role

Johnson drew on the Rat Park experiment to think about addiction as more than a matter of chemistry or inherited propensity. In that research, rats in isolated cages with access to drugs tended to consume them, while rats in enriched surroundings—with play, social contact, and exposure to nature—largely avoided the drugs. Johnson’s question was whether people experience the world as a prison or a playground. He suggested that a psychedelic experience might disrupt a narrowed inner world and make change conceivable even when a person’s history or surroundings remain painful.

In the account, Johnson’s significance lies in holding two claims together: psychedelic experience may loosen entrenched patterns, and its usefulness depends on how that experience is prepared, guided, and integrated. The proposed intervention is neither simply chemical nor simply conversational. It places therapeutic intention around an unusually suggestible state, treating the altered perspective as an opportunity rather than a guaranteed outcome—and a power requiring care rather than a remedy to be used without context.